INTELLIGENT BIO SOLUTIONS INC. — Director's Dealing 2023

Oct 7, 2023

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: INTELLIGENT BIO SOLUTIONS INC. (INBS)
CIK: 0001725430
Period of Report: 2023-10-04

Reporting Person: TOWERS CHRISTOPHER (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2023-10-04	Common Stock	P	9090	—	Acquired	9880	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2023-10-04	Common Stock Warrants (Series E)	$	P	9090	Acquired	2029-04-04	Common Stock (9090)	Direct
2023-10-04	Common Stock Warrants (Series F)	$	P	9090	Acquired	2025-04-04	Common Stock (9090)	Direct

Footnotes

F1: The reported securities are included within 9,090 INBS Class A Units purchased by the reporting person for $0.55 per Unit. Each Unit consists of one share of the common stock, one warrant to purchase one share of Common Stock at an exercise price of $0.55 per share ("Series E Warrants"), and one warrant to purchase one share of Common Stock at an exercise price of $0.55 per share ("Series F Warrants"). The Warrants will be exercisable beginning on the effective date of such stockholder approvals as may be required by the applicable rules and regulations of the Nasdaq Capital Market (or any successor entity) to permit the exercise of the Warrants ("Warrant Stockholder Approval").

F2: The exercise price of the Series E Warrants is $0.55 per share. However, under the one-time reset provision of the Series E Warrants, the exercise price of the Series E Warrants will reset to a price equal to the lesser of (i) the then exercise price and (ii) 90% of the five-day volume weighted average price for the five trading days immediately following the date the Company effects a reverse stock split.

F3: The exercise price of the Series F Warrants is $0.55 per share. However,under the alternate cashless exercise option of the Series F Warrants, the holder of the Series F Warrant (beginning on the date the Warrant Stockholder Approval is effective), has the right to receive an aggregate number of shares of Common Stock on a one-for-one basis (subject to adjustment).

F4: On February 9, 2023, the Issuer effected a 1-for-20 reverse stock split of its common stock (the "Reverse Split"). Unless otherwise noted, the amount of securities and purchase prices reported on this Form 4 have been adjusted to reflect the Reverse Split.